Praxis Precision Medicines (PRAX) Cash & Equivalents (2019 - 2026)

Praxis Precision Medicines' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $536.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 223.94% year-over-year to $536.3 million; the TTM figure through Mar 2026 stood at $536.3 million (up 223.94% YoY), while the FY2025 annual figure was $357.3 million, up 65.91% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $536.3 million, up from $357.3 million in the prior quarter.
• The five-year high for Cash & Equivalents was $536.3 million in Q1 2026, with the low at $56.0 million in Q2 2022.
• The 5-year median for Cash & Equivalents is $145.1 million (2024), against an average of $158.4 million.
• The sharpest annual moves came in 2022 and 2026: Cash & Equivalents tumbled 68.14% in 2022, then jumped 223.94% in 2026.
• Praxis Precision Medicines' Cash & Equivalents stood at $61.6 million in 2022, then soared by 31.95% to $81.3 million in 2023, then jumped by 164.91% to $215.4 million in 2024, then surged by 65.91% to $357.3 million in 2025, then surged by 50.1% to $536.3 million in 2026.
• Business Quant data shows PRAX's Cash & Equivalents at $536.3 million in Q1 2026, $357.3 million in Q4 2025, and $149.5 million in Q3 2025.